Publication
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Authors not recorded
Cancer Res Commun2024PMID 38126764PMC10860536stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (12)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 12
- cancerSolid Neoplasmcivic_curation1.00
- drugSapanisertibcivic_curation1.00
- geneAKT1civic_curation1.00
- geneAKT2civic_curation1.00
- geneMTORcivic_curation1.00
- genePIK3CAcivic_curation1.00
- genePTENcivic_curation1.00
- variantAKT1 Mutationcivic_curation1.00
- variantAKT2 Mutationcivic_curation1.00
- variantMTOR Mutationcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPTEN Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38126764
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AKT1 Mutation + AKT2 Mutation + MTOR Mutation + PIK3CA Mutation + PTEN MutationMTORPIK3CAPTENAKT1AKT21 | ||||||||
| Sapanisertib | Solid NeoplasmCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID12075In this study, 30 patients with advanced solid malignancies harboring mTOR/AKT/PI3K pathway alterations were treated with Sapanisertib. The tumor types included sarcomas, breast, ovarian, head and nec… (full text at CIViC) PMID 38126764 · Subbiah et al., 2024 · Open in CIViC | civic |